Oncology Clinical Trials in New Brunswick, NJ
As of June 2026, 134 paid clinical trials are recruiting for Oncology in New Brunswick, New Jersey. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
134 clinical trials for Oncology
·Clear filters·↓ Download CSVAdaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy
A Youth-led Intervention to Reduce Healthcare Disparities in Cancer Screening
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Digital Self-Management and Peer Mentoring Intervention
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer
SynKIR-310 for Relapsed/Refractory B-NHL
About research studies in New Brunswick
New Brunswick has approximately 366 recruiting research studies across a wide range of therapeutic areas. New Jersey hosts a diverse network of universities, academic medical centers, and community hospitals that run clinical trials across oncology, cardiology, neurology, and many other therapeutic areas.
Top Research Study Locations in New Brunswick
Researchers run research studies in New Brunswick, NJ at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Rutgers Cancer Institute of New Jersey | Breast Cancer, Acute Myeloid Leukemia, Multiple Myeloma | 124 |
| Rutgers Cancer Institute | Acute Myeloid Leukemia, Anal Cancer, Breast Cancer | 28 |
| Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital | B Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ganglioneuroblastoma, Nodular | 24 |
| Saint Peter's University Hospital | Acute Myeloid Leukemia, Malignant Solid Neoplasm, Acute Lymphoblastic Leukemia | 24 |
| Rutgers Robert Wood Johnson Medical School | Opioid Use, Acute Otitis Media, Aortic Stenosis, Calcific | 18 |
| Robert Wood Johnson University Hospital | Aortic Valve Insufficiency, Aortic Valve Stenosis, AMI | 16 |
| Rutgers University | Advanced Breast Cancer, Aneurysm, Brain, Anxiety | 11 |
| Robert Wood Johnson Medical School | ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome | 9 |
| RWJBarnabas Health - Robert Wood Johnson University Hospital | Cervical Cancer, Anal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma | 6 |
| Rutgers Cancer Institute of New Jersey | Breast Neoplasms, Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostate Cancer Metastatic | 6 |
| Cancer Institute of New Jersey | Anxiety, Caregiver Stress Syndrome, Metastases, Neoplasm | 5 |
| Rutgers | Aortoiliac Occlusive Disease, Breast Neoplasms, Carcinoma, Ductal, Breast | 4 |
| Rutgers - Robert Wood Johnson Medical School | Cystic Fibrosis, Cystic Fibrosis (CF), Cystic Fibrosis Pulmonary Exacerbation | 4 |
| GSK Investigational Site | Asthma, Neoplasms, Scleroderma, Systemic | 3 |
| Rutgers, The State University of New Jersey | Cervical Cancer, Coagulation Disorder, Papilloma Viral Infection | 3 |
| Saint Peter's University Hospital - New Brunswick | Cerebroside Lipidosis Syndrome, Fabry Disease, Gaucher Disease | 3 |
| Clinical Study Site | Metastatic Colorectal Cancer (CRC), Non-Small Cell Lung Cancer | 2 |
| Clinical Trial Site | Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL), Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Transthyretin Amyloidosis With Cardiomyopathy | 2 |
| Cooperman Barnabas Medical Center | Breast Cancer, Metastatic Breast Cancer, Metastatic Non Small Cell Lung Cancer | 2 |
| Rutgers Cancer Institute of NJ | Advanced Solid Malignancies, Endometrial Adenocarcinoma | 2 |
| Rutgers Health | Pancreatic Cystic Lesions, Triple Negative Breast Cancer | 2 |
| Rutgers University (Data Collection Only) | Hepatectomy, Malignant Mesothelioma, Malignant Peritoneal Mesothelioma | 2 |
| Rutgers, Robert Wood Johnson Medical School | Asthma, Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF) | 2 |
| Rutgers-Robert Wood Johnson Medical School | Amyloid Cardiomyopathy, Amyloidosis, Cardiogenic Shock | 2 |
| Exelixis Clinical | Solid Tumors, Advanced Solid Tumor | 2 |
Active & Upcoming Studies in New Brunswick (2026)
Recruiting trials in New Brunswick grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (191 active studies)
- Expanding Genetic Access for Prostate Cancer Survivors · Georgetown University
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) · Phase 1 · Eli Lilly and Company
Neurology & pain (14 active studies)
- FROST-STERN Trial: A Trial of Intraoperative Cryoablation for Post Operative Pain Management After Full Sternotomy · Rutgers, The State University of New Jersey
- Effects of Latin Dancing on Sleep Quality in Hispanic Cancer Survivors · Rutgers, The State University of New Jersey
Cardiovascular (13 active studies)
- A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation · Biosense Webster, Inc.
- INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery · Abiomed Inc.
Diabetes & metabolic (10 active studies)
- Virtual Diabetes Care for Adults With Type 2 Diabetes on Medicaid and Insulin Therapy · Rutgers, The State University of New Jersey
- Single vs Multi-Dose Insulin for Glycemic Control (SUGAR) · Rutgers, The State University of New Jersey
Mental health & behavior (8 active studies)
- Cigarette Filter Study · Rutgers, The State University of New Jersey
- Mindfulness-based Ecological Momentary Intervention for Smoking Cessation Among Cancer Survivors · Rutgers, The State University of New Jersey
Eye & vision (2 active studies)
- Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes · Iantrek, Inc.
- A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration · Phase 1 · Astellas Institute for Regenerative Medicine
Vaccines (1 active study)
Pediatric (1 active study)
- Digital Self-Management and Peer Mentoring Intervention · Rutgers, The State University of New Jersey
Common conditions studied in New Brunswick
- Breast Cancer (17 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Acute Myeloid Leukemia (11 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Cancer (7 active studies). Recruiting Cancer studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Multiple Myeloma (7 active studies). Recruiting Multiple Myeloma studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Breast Neoplasms (6 active studies). Recruiting Breast Neoplasms studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Melanoma (6 active studies). Melanoma trials test immune checkpoint inhibitors, adoptive cell therapies, and BRAF/MEK targeted combinations in both early and metastatic disease.
Leading research sponsors in New Brunswick
- Rutgers, The State University of New Jersey
- National Cancer Institute (NCI)
- Children's Oncology Group
- Merck Sharp & Dohme LLC
- NRG Oncology
Local regulations and guidelines
Clinical trials in New Jersey are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. New Jersey research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in New Brunswick. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in New Brunswick
Hipa.ai aggregates every recruiting study in New Brunswick from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in New Brunswick?
There are approximately 366 recruiting clinical trials in New Brunswick, New Jersey listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in New Brunswick pay participants?
Most recruiting trials in New Brunswick compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in New Brunswick?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in New Brunswick?
The most common conditions under active study in New Brunswick include Breast Cancer (17), Acute Myeloid Leukemia (11), Cancer (7), Multiple Myeloma (7), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in New Brunswick?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in New Brunswick on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in New Brunswick?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in New Brunswick?
Recruiting research sites in New Brunswick include Rutgers Cancer Institute of New Jersey, Rutgers Cancer Institute, Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in New Brunswick right now?
The largest active categories in New Brunswick are Cancer & tumors (191), Neurology & pain (14), Cardiovascular (13). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.